Home Cart Sign in  
Chemical Structure| 150080-09-4 Chemical Structure| 150080-09-4

Structure of Talabostat mesylate
CAS No.: 150080-09-4

Chemical Structure| 150080-09-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active, nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM). It also inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and other DASH family enzymes, exhibiting antineoplastic and hematopoiesis-stimulating activities.

Synonyms: PT100 mesylate; Val-boroPro mesylate; Talabostat (mesylate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Talabostat mesylate

CAS No. :150080-09-4
Formula : C10H23BN2O6S
M.W : 310.17
SMILES Code : CS(=O)(O)=O.CC(C)[C@H](N)C(N1[C@H](B(O)O)CCC1)=O
Synonyms :
PT100 mesylate; Val-boroPro mesylate; Talabostat (mesylate)
MDL No. :MFCD13194906
InChI Key :OXYYOEIGQRXGPI-WSZWBAFRSA-N
Pubchem ID :11522448

Safety of Talabostat mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00489710 Kidney Cancer Phase 2 Withdrawn(Terminated for safet... More >>y reasons) Less << - -
NCT02083120 Pulmonary Disease, Chronic Obs... More >>tructive Less << Not Applicable Active, not recruiting November 2018 Germany ... More >> Helios Klinik Ambrock Hagen, NRW, Germany, 58091 Less <<
NCT00083239 Melanoma Skin... More >> Cancer Less << Phase 2 Completed - United States, Georgia ... More >> Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322-1013 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109-0473 United States, New Hampshire Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756-0001 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213-2582 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75246 Less <<
NCT00080080 Lung Cancer Phase 2 Completed - United States, Florida ... More >> Cancer Center of Florida Ocoee, Florida, United States, 34761 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan Van Elslander Cancer Center Grosse Pointe Woods, Michigan, United States, 48236 United States, New York New York Oncology/Hematology--Albany Regional Cancer Center Albany, New York, United States, 12208 Mt. Sinai School of Medicine New York, New York, United States, 10029 USB Cancer Center-- Nyack Hospital Nyack, New York, United States, 10960 United States, Ohio Dayton Oncology & Hematology Kettering, Ohio, United States, 45409 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75246 Tyler Cancer Center Tyler, Texas, United States, 75702 United States, Washington Cancer Care Northwest Spokane, Washington, United States, 99218 Less <<
NCT00083252 Melanoma Skin... More >> Cancer Less << Phase 2 Completed - United States, Arkansas ... More >> University of Arkansas Medical Sciences Little Rock, Arkansas, United States, 72205 United States, California Cancer Institute Medical Group, Inc. Santa Monica, California, United States, 90404 United States, Colorado University of Colorado Health Sciences Center Aurora, Colorado, United States, 80045 United States, Florida Cancer Center of Florida Ocoee, Florida, United States, 34761 United States, Indiana Indiana Hematology Oncology Consultants Indianapolis, Indiana, United States, 46202 United States, New Mexico New Mexico Cancer Center Alliance Albuquerque, New Mexico, United States, 87106 United States, New York NYU School of Medicine New York, New York, United States, 10016 Fifth Avenue Medical Healthcare New York, New York, United States, 10128 United States, North Carolina Carolinas Medical Center Charlotte, North Carolina, United States, 28203 United States, South Carolina Cancer Center of the Carolinas Greenville, South Carolina, United States, 29615 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75246 Tyler Cancer Center Tyler, Texas, United States, 75702 United States, Washington Cancer Care Northwest Research Spokane, Washington, United States, 99218 Less <<
NCT00086203 Chronic Lymphocytic Leukemia Phase 2 Completed - United States, Arkansas ... More >> University of Arkansas for Medical Science Little Rock, Arkansas, United States, 72205 United States, Florida Ocala Oncology Center Ocala, Florida, United States, 34474 Gulfcoast Oncology Associates St. Petersburg, Florida, United States, 33705 United States, Indiana Indiana Oncology/Hematology Consultants Indianapolis, Indiana, United States, 46202 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Montana Hematology/Oncology Centers of the Northern Rockies Billings, Montana, United States, 59101 United States, Nevada Nevada Cancer Institute Las Vegas, Nevada, United States, 89135 United States, New York Queens Medical Associates, PC Fresh Meadows, New York, United States, 11365 Long Island Jewish Medical Center New Hyde Park, New York, United States, 11040 NYU Medical Center New York, New York, United States, 10016 James P. Wilmot Cancer Center/University of Rochester Rochester, New York, United States, 14642 United States, North Carolina Raleigh Hematology/Oncology Clinic Cary, North Carolina, United States, 27511 Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Oklahoma Cancer Care Associates/Oklahoma City Oklahoma City, Oklahoma, United States, 73112 Cancer Care Associates--Tulsa Tulsa, Oklahoma, United States, 74136 United States, South Carolina Cancer Centers of the Carolinas Seneca, South Carolina, United States, 29672 United States, Texas Texas Cancer Center/Abilene Abilene, Texas, United States, 79606-5208 MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Virginia Virginia Oncology Associates-Lake Wright Cancer Center Norfolk, Virginia, United States, 23502 Less <<
NCT00116389 Pancreatic Cancer ... More >> Neoplasm Metastasis Adenocarcinoma Less << Phase 2 Terminated(FDA Hold May 2007) - -
NCT00243204 Carcinoma, Non-Small Cell Lung Phase 3 Terminated(FDA Hold May 2007) - -
NCT00303940 Brain and Central Nervous Syst... More >>em Tumors Childhood Germ Cell Tumor Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.22mL

0.64mL

0.32mL

16.12mL

3.22mL

1.61mL

32.24mL

6.45mL

3.22mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.

References

 

Historical Records

Categories